Bank Of New York Mellon Corp Ngm Biopharmaceuticals Inc Transaction History

Bank Of New York Mellon Corp

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$3.41 - $12.93 $454,945 - $1.73 Million	133,415 New	133,415 $669,000
Q3 2022 Nov 14, 2022	BUY	$12.59 - $17.67 $249,785 - $350,572	19,840 Added 15.17%	150,629 $1.97 Million
Q2 2022 Aug 15, 2022	SELL	$10.58 - $17.5 $18,250 - $30,187	-1,725 Reduced 1.3%	130,789 $1.68 Million
Q1 2022 May 11, 2022	BUY	$13.81 - $18.6 $53,762 - $72,409	3,893 Added 3.03%	132,514 $2.02 Million
Q4 2021 Feb 11, 2022	BUY	$17.26 - $22.02 $196,539 - $250,741	11,387 Added 9.71%	128,621 $2.28 Million
Q3 2021 Nov 12, 2021	BUY	$20.15 - $26.19 $319,236 - $414,928	15,843 Added 15.63%	117,234 $2.47 Million
Q2 2021 Aug 11, 2021	BUY	$15.06 - $30.03 $325,823 - $649,699	21,635 Added 27.13%	101,391 $2 Million
Q1 2021 May 13, 2021	SELL	$24.99 - $31.93 $84,941 - $108,530	-3,399 Reduced 4.09%	79,756 $2.32 Million
Q4 2020 Feb 09, 2021	SELL	$16.21 - $31.44 $30,653 - $59,453	-1,891 Reduced 2.22%	83,155 $2.52 Million
Q3 2020 Nov 12, 2020	BUY	$15.59 - $19.97 $60,130 - $77,024	3,857 Added 4.75%	85,046 $1.35 Million
Q2 2020 Aug 12, 2020	SELL	$11.97 - $23.47 $13,238 - $25,957	-1,106 Reduced 1.34%	81,189 $1.6 Million
Q1 2020 May 06, 2020	BUY	$10.0 - $19.51 $235,670 - $459,792	23,567 Added 40.13%	82,295 $1.01 Million
Q4 2019 Feb 14, 2020	BUY	$9.97 - $20.28 $336,896 - $685,281	33,791 Added 135.51%	58,728 $1.09 Million
Q3 2019 Nov 07, 2019	BUY	$13.09 - $18.19 $169,227 - $235,160	12,928 Added 107.65%	24,937 $345,000
Q2 2019 Aug 12, 2019	BUY	$12.56 - $16.6 $150,833 - $199,349	12,009 New	12,009 $176,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.